Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Jie Zhang,Wenjuan Yang,Jie Ji,Liwei Wu,Jiao Feng,Qiang Yu,Yuanyuan Zheng,Yan Li,Ziqi Cheng,Jianye Wu,Jingjing Li,Chuanyong Guo

DOI: https://doi.org/10.2139/ssrn.4129095

2022-01-01

SSRN Electronic Journal

Abstract:Liver fibrosis is a concomitant pathological process in the development of chronic liver diseases, which characterized by hepatic stellate cell activation and abnormal extracellular matrices deposition. Fenofibrate has extensively studied in non-alcoholic fatty liver disease, primary sclerosing cholangitis and primary biliary cirrhosis, which provide indirect evidence of its anti-fibrotic function, but its solely direct mechanisms remain obscure. Here, our objective was to investigate the protective effect of fenofibrate on the two types of experimental mice fibrosis models as well as the in vitro hepatic stellate cells. In vivo hepatic fibrosis was induced in male C57 mice using carbon tetrachloride intraperitoneally and performing bile duct ligation surgery. Fenofibrate administration was at doses of 50 and 100 mg/kg by oral gavage. TGF-β1 activated LX2 cell model was also generated to further prove the role of fenofibrate. Results revealed that fenofibrate alleviated liver fibrosis by inhibiting the activation of hepatic stellate cells and extracellular matrix formation, and this action was most likely associated with autophagy and oxidative stress by regulating PPAR-α and TGF-β1/Smad pathway. This may provide a therapeutic option for hepatic fibrosis.